OBJECTIVES: This study aims to investigate the correlation between serum anti-heat-shock protein 70 (anti-HSP 70) levels, serum paraoxonase (PON) levels and prognosis of idiopathic sudden sensorineural hearing loss (ISSHL). PATIENTS AND METHODS: Twenty-five patients with ISSHL as the study group and 25 healthy volunteers as the control group were enrolled in this study. Blood samples were obtained from all patients before the treatment initiation and on the 10th day of the treatment from only patients of the study group. Idiopathic sudden sensorineural hearing loss was defined as the hearing loss between 250-6.000 Hz frequencies. The recoveries in the hearing thresholds were evaluated at 10 days of the treatment. RESULTS: When the pre-treatment serum PON, anti-HSP 70 levels and the post-treatment serum PON, anti-HSP 70 levels of the patients with ISSHL were compared, we observed that the post-treatment serum PON levels of the recovered patients increased, while the post-treatment serum anti-HSP 70 levels of recovered patients decreased. CONCLUSION: We believe that serum levels of anti-HSP 70 and PON can be used as markers for estimating and evaluating the prognosis of ISSHL patients.
OBJECTIVES: This study aims to investigate the correlation between serum anti-heat-shock protein 70 (anti-HSP 70) levels, serum paraoxonase (PON) levels and prognosis of idiopathic sudden sensorineural hearing loss (ISSHL). PATIENTS AND METHODS: Twenty-five patients with ISSHL as the study group and 25 healthy volunteers as the control group were enrolled in this study. Blood samples were obtained from all patients before the treatment initiation and on the 10th day of the treatment from only patients of the study group. Idiopathic sudden sensorineural hearing loss was defined as the hearing loss between 250-6.000 Hz frequencies. The recoveries in the hearing thresholds were evaluated at 10 days of the treatment. RESULTS: When the pre-treatment serum PON, anti-HSP 70 levels and the post-treatment serum PON, anti-HSP 70 levels of the patients with ISSHL were compared, we observed that the post-treatment serum PON levels of the recovered patients increased, while the post-treatment serum anti-HSP 70 levels of recovered patients decreased. CONCLUSION: We believe that serum levels of anti-HSP 70 and PON can be used as markers for estimating and evaluating the prognosis of ISSHL patients.